Stefan Kasper

Goethe University Frankfurt — Germany

Medicine · Health Sciences

36h-index12.9kcitations297works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(90), Cancer Immunotherapy and Biomarkers(80), Lung Cancer Treatments and Mutations(47), Gastric Cancer Management and Outcomes(35), Cholangiocarcinoma and Gallbladder Cancer Studies(35)

Publications294 total

Supplementary Data1 from Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
2025Open Access
Automated CT-based sarcopenia assessment for risk stratification of patients undergoing colorectal cancer resection
Clinical Surgical Oncology·2025Open Access
Clinical practice and implications of biomarker testing in biliary tract cancer: An observational study
JHEP Reports·2025Open Access
OncoVR - Virtual Reality in Oncology for Patient-centered Care: A Systematic Review and Meta-Analysis
2025Open Access
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification
npj Digital Medicine·2025· 1 citedOpen Access
Supplementary Table S12 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S9 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S8 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S2 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S10 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S7 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S13 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S6 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for <i>RAS</i> wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
2025Open Access
page 1 of 15Next →

Frequent Co-authors

Martin Schüler(24), Jérôme Fayette(11), Lisa Licitra(11), Kevin J. Harrington(11), Robert I. Haddad(11), Maura L. Gillison(11), Frank Breitenbuecher(11), Robert L. Ferris(10), George R. Blumenschein(10), J. Guigay(10), Everett E. Vokes(10), Makoto Tahara(10), A. Dimitrios Colevas(9), Francis P. Worden(9), Nabil F. Saba(9), Mark Lynch(9), Caroline Even(8), Naomi Kiyota(8), Kurt Werner Schmid(7), Marcel Wiesweg(7)